Relationship between PD-L1 expression, CD8+T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients

被引:39
作者
Deng, Min [1 ,2 ,3 ]
Li, Shao-Hua [1 ,2 ,3 ]
Fu, Xu [4 ]
Yan, Xiao-Peng [4 ]
Chen, Jun [5 ]
Qiu, Yu-Dong [4 ]
Guo, Rong-Ping [1 ,2 ,3 ]
机构
[1] Sun Yat Sen Univ Canc Ctr, Dept Liver Surg, 651 Dongfeng East Rd, Guangzhou, Peoples R China
[2] State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[4] Nanjing Univ, Dept Hepatopancreatobiliary Surg, Med Sch, Nanjing Drum Tower Hosp,Affiliated Hosp, 321 Zhong Shan Rd, Nanjing, Jiangsu, Peoples R China
[5] Nanjing Univ, Dept Pathol, Affiliated Hosp, Med Sch,Nanjing Drum Tower Hosp, Nanjing, Peoples R China
基金
中国国家自然科学基金;
关键词
Intrahepatic; Cholangiocarcinoma; Programmed death-ligand 1; CD8+T cell; Prognosis; CARCINOMA; DIAGNOSIS; LIGAND-1; PATHWAY; CANCER;
D O I
10.1186/s12935-021-02081-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Programmed death- ligand 1 (PD-L1) seems to be associated with the immune escape of tumors, and immunotherapy may be a favorable treatment for PD-L1-positive patients. We evaluated intrahepatic cholangiocarcinoma (ICC) specimens for their expression of PD-L1, infiltration of CD8+ T cells, and the relationship between these factors and patient survival. Methods In total, 69 resections of ICC were stained by immunohistochemistry for PD-L1, programmed death factor-1 (PD-1), and CD8+ T cells. CD8+ T-cell densities were analyzed both within tumors and at the tumor-stromal interface. Patient survival was predicted based on the PD-L1 status and CD8+ T-cell density. Results The expression rate of PD-L1 was 12% in cancer cells and 51% in interstitial cells. The expression rate of PD-1 was 30%, and the number of CD8+ T-cells increased with the increase of PD-L1 expression (p < 0.05). The expression of PD-L1 in the tumor was correlated with poor overall survival(OS) (p = 0.004), and the number of tumor and interstitial CD8+ T-cells was correlated with poor OS and disease-free survival (DFS) (All p < 0.001). Conclusions The expression of PD-L1 in the tumor is related to poor OS, and the number of tumor or interstitial CD8+ T-cells is related to poor OS and DFS. For patients who lose their chance of surgery, PD-L1 immunosuppressive therapy may be the focus of future research as a potential treatment.
引用
收藏
页数:10
相关论文
共 41 条
[1]  
Afreen Sehar, 2014, Hematol Oncol Stem Cell Ther, V7, P1, DOI 10.1016/j.hemonc.2013.09.005
[2]   Epidemiology of cholangiocarcinoma [J].
Bergquist, Annika ;
von Seth, Erik .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2015, 29 (02) :221-232
[3]   PD-L1 Expression as a Predictive Biomarker Is Absence of Proof the Same as Proof of Absence? [J].
Bhaijee, Feriyl ;
Anders, Robert A. .
JAMA ONCOLOGY, 2016, 2 (01) :54-55
[4]   Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma [J].
Bridgewater, John ;
Galle, Peter R. ;
Khan, Shahid A. ;
Llovet, Josep M. ;
Park, Joong-Won ;
Patel, Tushar ;
Pawlik, Timothy M. ;
Gores, Gregory J. .
JOURNAL OF HEPATOLOGY, 2014, 60 (06) :1268-1289
[5]   Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship With Clinical and Pathological Features [J].
Calderaro, Julien ;
Rousseau, Benoit ;
Amaddeo, Giuliana ;
Mercey, Marion ;
Charpy, Cecile ;
Costentin, Charlotte ;
Luciani, Alain ;
Zafrani, Elie-Serge ;
Laurent, Alexis ;
Azoulay, Daniel ;
Lafdil, Fouad ;
Pawlotsky, Jean-Michel .
HEPATOLOGY, 2016, 64 (06) :2038-2046
[6]   Cholangiocarcinoma - Thirty-one-year experience with 564 patients at a single institution [J].
DeOliveira, Michelle L. ;
Cunningham, Steven C. ;
Cameron, John L. ;
Kamangar, Farin ;
Winter, Jordan M. ;
Lillemoe, Keith D. ;
Choti, Michael C. ;
Yeo, Charles J. ;
Schulick, Richard D. .
ANNALS OF SURGERY, 2007, 245 (05) :755-762
[7]   Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer [J].
Donnem, Tom ;
Hald, Sigurd M. ;
Paulsen, Erna-Elise ;
Richardsen, Elin ;
Al-Saad, Samer ;
Kilvaer, Thomas K. ;
Brustugun, Odd Terje ;
Helland, Aslaug ;
Lund-Iversen, Marius ;
Poehl, Mette ;
Olsen, Karen Ege ;
Ditzel, Henrik J. ;
Hansen, Olfred ;
Al-Shibli, Khalid ;
Kiselev, Yury ;
Sandanger, Torkjel M. ;
Andersen, Sigve ;
Pezzella, Francesco ;
Bremnes, Roy M. ;
Busund, Lill-Tove .
CLINICAL CANCER RESEARCH, 2015, 21 (11) :2635-2643
[8]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[9]   Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC [J].
Gabrielson, Andrew ;
Wu, Yunan ;
Wang, Hongkun ;
Jiang, Jiji ;
Kallakury, Bhaskar ;
Gatalica, Zoran ;
Reddy, Sandeep ;
Kleiner, David ;
Fishbein, Thomas ;
Johnson, Lynt ;
Island, Eddie ;
Satoskar, Rohit ;
Banovac, Filip ;
Jha, Reena ;
Kachhela, Jaydeep ;
Feng, Perry ;
Zhang, Tiger ;
Tesfaye, Anteneh ;
Prins, Petra ;
Loffredo, Christopher ;
Marshall, John ;
Weiner, Louis ;
Atkins, Michael ;
He, Aiwu Ruth .
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (05) :419-430
[10]   Innate and adaptive immune cells in the tumor microenvironment [J].
Gajewski, Thomas F. ;
Schreiber, Hans ;
Fu, Yang-Xin .
NATURE IMMUNOLOGY, 2013, 14 (10) :1014-1022